share_log

Needham Reiterates Buy on BioCryst Pharma, Lowers Price Target to $12

Benzinga ·  Aug 3, 2023 13:27

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $14 to $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment